Close
Nordic 9Nordic 9

TCGX (investor - Venture Capital)

United States tcgcrossover.com
See something wrong or missing? Let us know
Offices:San Francisco

TCG Crossover is an American science-driven investment firm dedicated to advancing disruptive medicines

Average round investment:128M USD
Average number per year:2.5
Distribution: 2025 (1)2024 (4)
Portfolio companies: United Kingdom Artios PharmaDenmark AdcendoUnited Kingdom Vicebio See the entire list
Mostly invests in: United Kingdom United Kingdom (4) Health services (5)
See the entire list

Showing 3 of 5 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to TCGX

Name Criteria
Denmark Axcel
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
United States Viking Global Investors
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
United Arab Emirates Chimera Investment
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
South Korea LG Electronics
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Denmark ATP
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
United States Honeywell Ventures
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Norway Watrium
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Wellington Management
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United States Alpha Wave Global
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Ridgeback Capital Management
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top